BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions BREAKING: The FDA just made it official. Advisory committee meetings are now scheduled for July 23 24 to review reclassifying peptides back to legal compounding status. Here's what's happening: After the The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics Is BPC 157 Banned? Oral vs. Injectable Forms Explained